Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population.

AIMS We decided to determine the long-term survival of patients after alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) and compare this with the general population. METHODS AND RESULTS A total of 178 highly symptomatic, consecutive patients (58 ± 12 years, 53% women) were treated by ASA between April 1998 and April 2013 and followed-up for 4.8 years (IQR 2.1-7.5). At baseline, 155 patients (87%) suffered from dyspnoea ≥3 class of NYHA; at the most recent examination, 87 patients (49%) and 23 patients (13%) reported dyspnoea of NYHA class 1 and ≥3, respectively. The left ventricular outflow gradient was significantly reduced (68 ± 42 vs. 20 ± 25 mmHg; P < 0.01). A total of 19 deaths (11%) occurred during 925 patient-years, which means an overall mortality rate of 2.1% per year. Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 93-99%), 92% (95% CI, 87-96%), and 82% (95% CI, 70-90%), respectively. This observed mortality was comparable to the expected survival for age- and sex-comparable general population (P = 0.34). According to multivariate analysis, the only independent predictor of all-cause mortality was age at ASA (hazard ratio 1.09, 95% CI 1.04-1.14; P < 0.01). CONCLUSIONS This study suggests that in patients with HOCM and important symptoms who underwent ASA, long-term survival after the procedure did not differ significantly from that of the general population.

[1]  H. Bundgaard,et al.  Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile , 2013, Heart.

[2]  W. Manning,et al.  Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age , 2013, Circulation.

[3]  P. Lambiase,et al.  A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy , 2013, Heart.

[4]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[5]  W. McKenna,et al.  Insights and challenges in hypertrophic cardiomyopathy, 2012 , 2012, Herzschrittmachertherapie & Elektrophysiologie.

[6]  S. Warach,et al.  Standardizing the Structure of Stroke Clinical and Epidemiologic Research Data: The National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) Project , 2012, Stroke.

[7]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[8]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[9]  P. Elliott.  The role of alcohol septal ablation in the treatment of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[10]  B. Groves,et al.  Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. , 2011, Journal of the American College of Cardiology.

[11]  J. Veselka,et al.  Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. , 2011, The Canadian journal of cardiology.

[12]  L. Køber,et al.  Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy , 2011, Scandinavian cardiovascular journal : SCJ.

[13]  L. Køber,et al.  Long-Term Outcome of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: A Scandinavian Multicenter Study , 2011, Circulation. Cardiovascular interventions.

[14]  K. Fox,et al.  Long-Term Follow-Up of the First Patients to Undergo Transcatheter Alcohol Septal Ablation , 2010, Cardiology.

[15]  J. Veselka,et al.  Real-time myocardial contrast echocardiography for echo-guided alcohol septal ablation , 2009 .

[16]  N. Lakkis,et al.  Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. , 2009, European heart journal.

[17]  J. Veselka,et al.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective , 2009, Heart and Vessels.

[18]  S. Nagueh,et al.  Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. , 2008, JACC. Cardiovascular interventions.

[19]  N. Smedira,et al.  Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. , 2008, JACC. Cardiovascular interventions.

[20]  J. Breall,et al.  Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2008, Current cardiology reviews.

[21]  C. Stellbrink,et al.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.

[22]  J. Veselka.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[23]  L. Faber.  Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. , 2006, European journal of medical research.

[24]  N. Lakkis,et al.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. , 2006, Journal of interventional cardiology.

[25]  J. Veselka,et al.  Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[26]  H. Watkins,et al.  The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[27]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[28]  J. Veselka,et al.  Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. , 2005, The American journal of cardiology.

[29]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[30]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[31]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[32]  Dutra Vfd,et al.  SYSTEMATIC REVIEW OF LITERATURE , 2014 .

[33]  M.B.B.S. M.D. Fesc Srijita Sen-Chowdhry M.A.,et al.  Insights and challenges in hypertrophic cardiomyopathy, 2012 , 2012, Herzschrittmachertherapie + Elektrophysiologie.

[34]  S. Ommen,et al.  Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[35]  A. Rigopoulos,et al.  A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[36]  M. Ragosta.  Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2011 .